Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER(−)) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Qiang, Peyvandi, Sanam, Duffey, Nathalie, Huang, Yu-Ting, Barras, David, Held, Werner, Richard, François, Delorenzi, Mauro, Sotiriou, Christos, Desmedt, Christine, Lorusso, Girieca, Rüegg, Curzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477891/
https://www.ncbi.nlm.nih.gov/pubmed/30546090
http://dx.doi.org/10.1038/s41388-018-0624-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477891/
https://www.ncbi.nlm.nih.gov/pubmed/30546090
http://dx.doi.org/10.1038/s41388-018-0624-2

Ejemplares similares